Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies

Summary

Combined analyses of the pairs of biomarkers A IGHV mutation status and CD49d, B IGHV mutation status and telomere length and C telomere length and CD49d as predictors of progression-free survival (PFS) in CLL patients. D Shows the overlaid Kaplan–Meier curves for the ARCTIC/ADMIRE cohort, which demonstrate that patients with mutated IGHV genes and short telomeres have a similar, inferior PFS to the unmutated IGHV subset. Furthermore, patients with mutated IGHV genes, long telomeres and low CD49d expression have a significantly longer PFS than patients with mutated IGHV genes, long telomeres and high CD49d expression. E An additional cohort, derived from the FC-treated arm of the UK CLL4 trial, confirmed the findings from the ARCTIC/ADMIRE cohort. F Shows a schematic diagram of the propose a risk-adapted approach to treatment selection, which would contra-indicate frontline chemoimmunotherapy for ~83% of patients.

Andrea Pepper

Professor of Cancer Biology

Professor of Cancer Biology interested in modelling the tumour microenvironment and trafficking, tumour cell signalling, haematological malignancies and drug testing

Chris Pepper

Professor of Cancer Research

Professor of Cancer Research interested in tumour microenvironment and trafficking, drug development, haematological malignancies, telomere biology and NF-κB